Although the intention-to-treat analysis for overall survival narrowly missed statistical significance, the prespecified per-protocol analysis showed a clear survival benefit (median overall survival 53 vs. 36 months; HR 0.75) [ 80 ].
← all excerpts
Recent advances in molecular classification and multimodal treatment of intrahepatic cholangiocarcinoma.
1
—
—